<form id="jhhvn"></form><form id="jhhvn"><th id="jhhvn"><track id="jhhvn"></track></th></form>

    <address id="jhhvn"><address id="jhhvn"><nobr id="jhhvn"></nobr></address></address>
      <address id="jhhvn"></address>

      www.mebliok.com 提示:

      本信息僅供醫學專業人士參考,如果您是醫學專業人士,請點擊確定后進入。 如果不是,請點擊取消。

      取消 確定

      Products and services

      In 3SBio, meeting the needs of patients is the core of all actions.

      Our global list of drug combinations

      The following is a list of products listed by our company, which is only for medical professionals to refer to.

      YISAIPU (Recombinant human type II tumor necrosis factor receptor - antibody fusion protein)

      YISAIPU was marketed in 2005 and is the first antibody fusion protein medicine marketed in the rheumatism field of China. 3 kinds of indications were approved by the NMPA: Treatment of rheumatoid arthritis (approved in 2005), ankylosing spondylitis and psoriasis (approved in 2007). It is included in the National Medical Insurance Catalogue as a Category B drug of western medicine.

      Indication Manufacturing base Dosage form & Dosage
      Moderate to severe rheumatoid arthritis;
      Moderate to severe plaque psoriasis (PS) in adults aged 18 or above;
      Active ankylosing spondylitis.
      Shanghai manufacturing base 12.5 mg/bottle; 25 mg/bottle
      九九99热久久精品在线22,不卡岛国aV一区二区,91在线视频观看免费,国产swag视频在线,欧美 日韩 国产 自拍在线视频,国产在线观看主播自慰,少女萝莉映画视频,手机国产网红主播视频福利